• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Arthritis News / Pregnancy Outcomes in Patients with Rheumatoid Arthritis and Lupus

Pregnancy Outcomes in Patients with Rheumatoid Arthritis and Lupus

June 19, 2006 By Arthritis Center

Changes in disease activity during pregnancy and the peri-partum period have long been recognized features of systemic autoimmune disease. Moreover, as certain autoimmune diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), frequently affect women of childbearing age, there is the potential for the disease to affect pregnancy outcomes. However, despite the frequency of pregnancy in women affected by these disorders, pregnancy outcomes are understudied. Here, Chakravarty et al (Arthritis Rheum 2006; 54: 899) examine pregnancy outcomes in SLE and RA utilizing a large, nationwide administrative dataset.

Methods

 Pregnancy outcomes from all hospitalizations attributed to patients coded for the diagnoses of SLE, RA, antiphospholipid antibody syndrome (APS), or gestational diabetes (GDM) were collected from the 2002 Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project. This administrative database contains discharge data from all of the inpatient hospitalizations of 995 hospitals in 35 geographically diverse states, representing 20% of non-federal hospitals in the U.S. Pregnancy outcomes of interest included antenatal hospitalization, hypertensive disorders (including preeclampsia), cesarean section, and intra-uterine growth retardation (IUGR).

Results

 Of the 976,527 total obstetric hospitalizations, 943 were in patients with a diagnosis of SLE, 360 with RA, 719 with APS, and 8338 with GDM. Most (95%) of the women with a diagnosis of APS did not carry an additional diagnosis of SLE or RA. Sampling weights were used to estimate the total number of obstetric hospitalizations, total deliveries, and cesarean deliveries in the U.S. in 2002 by diagnosis:

Point estimates for total obstetric hospitalizations, deliveries, and cesarean deliveries in the U.S. for 2002 by diagnosis

SLE RA APS GDM
All obstetric hospitalizations 4425 1685 3398 38713
Deliveries 3264 1425 2884 24427
Cesarean deliveries 1266 516 1285 13574

Non-delivery hospitalizations were statistically significantly higher in women with SLE (26.3%: p<0.001), RA (15.6%; p=0.006), APS (15.2%; p=0.006), and GDM (38.1%; p<0.001), compared to women without one of these diagnoses (11.2%).

Pregnancy outcomes in SLE At delivery, women with SLE tender to be older than non-SLE control patients (mean age 29.6 vs. 27.5 years, respectively). In SLE patients compared to controls, the rates of hypertensive disorders (23.2% vs. 7.8%, respectively), IUGR (5.3% vs. 1.6%, respectively), and cesarean section (39.4% vs. 26.5%, respectively) were significantly higher in the SLE group (p < 0.001 for all three outcomes). Age adjusted odds ratios are presented in the table below.

Pregnancy outcomes in RA At delivery, women with RA tender to be older than non-RA control patients (mean age 29.8 vs. 27.5 years, respectively). In RA patients compared to controls, the rates of hypertensive disorders (11.1% vs. 7.8%, respectively), IUGR (3.4% vs. 1.6%, respectively), and cesarean section (37.2% vs. 26.5%, respectively) were significantly higher in the RA group (p < 0.01 for all three outcomes). Age adjusted odds ratios are presented in the table below.

Pregnancy outcomes in APS At delivery, women with APS tender to be older than non-APS control patients (mean age 31.3 vs. 27.5 years, respectively). In APS patients compared to controls, the rates of hypertensive disorders (13.0% vs. 7.8%, respectively), IUGR (5.1% vs. 1.6%, respectively), and cesarean section (44.6% vs. 26.5%, respectively) were significantly higher in the APS group (p < 0.001 for all three outcomes). Age adjusted odds ratios are presented in the table below.

Age adjusted risk of adverse pregnancy outcomes compared to control patients according to diagnosis

SLE RA APS GDM
Hypertensive disorders 3.3
(2.8 4.0)
1.4
(0.9 1.9)
1.6
(1.3 2.0)
4.4
(4.2 4.7)
IUGR 3.5
(2.5 4.9)
2.2
(1.2 4.1)
3.4
(2.4 4.9)
1.1
(0.9 1.5)
Cesarean section 1.6
(1.4 1.9)
1.5
(1.2 1.9)
1.9
(1.6 2.2)
3.2
(3.0 3.4)

African-American race was associated with an increased risk of all adverse pregnancy outcomes examined.

Conclusions

 To varying degrees, adverse pregnancy outcomes are significantly more frequent in women with SLE, RA, and APS than in women who do not carry these diagnoses.

Editorial Comment

 The primary advantage of this study derives from the size and scope of the dataset utilized, by far the largest and most geographically diverse analysis to date devoted to pregnancy outcomes in women with autoimmune disease.

However, whenever administrative databases of this sort are utilized, issues of misclassification may result; particularly as the data was not collected with the aims of this investigation in mind but primarily for reimbursement purposes. Thus, patients with mild or inactive disease may not be diagnostically coded if their autoimmune disease was not thought to impact their hospitalization. The patients left with more active or severe disease may also be those more prone to adverse outcomes, with the ultimate result of adverse outcome rates being overestimated.

In addition, because no clinical data was examined it is impossible in this analysis to determine the individual risk factors for the adverse pregnancy outcomes within the diagnostic groups. In particular, understanding the impact of disease activity during pregnancy, and the effect of medications used to control disease activity, are important understudied questions that frequently face women with autoimmune disease contemplating pregnancy and their caregivers. However, investigations such as the one presented here suggest that interest in this challenging area of clinical investigation is increasing.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy